close
MENU
Hot Topic Hawke’s Bay
How to guide
How to guide
Home
The NBR List
NBR View
NBR Marketplace

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

Podcasts Audio Articles Entrepreneurs Your Business Beehive Banter Morning Brew Toil & Trouble NZ Aviation News Back Issues Market Outlook Dollars & Sense Private Bin Opinion (Archive) NBR Radar (Archive) NBR Rich List (Archive)
Hot Topic Hawke’s Bay
General Business
3 mins to read
3

OIO greenlights NZP sale to Boston private equity fund

The Palmerston North manufacturer now has the same owner as an Italian pharma giant.

Julie Iles Mon, 31 Aug 2020

The sale of New Zealand Pharmaceuticals, a Palmerston North-based specialty chemical manufacturer, for an undisclosed amount to a Boston-based private equity firm has been given Overseas Investment Office (OIO) approval.

The company, which was previously owned by Australian private equity firm

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Julie Iles Mon, 31 Aug 2020
Contact the Writer: julie@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
New Zealand Pharmaceuticals Ice Group private equity OIO decision
Related News

NZ Pharmaceuticals turns defence into offence for alternative bile supply

NZ Pharmaceuticals gets $49.6m cash injection as Archer Capital takes over
Related News

NZ Pharmaceuticals turns defence into offence for alternative bile supply

NZ Pharmaceuticals gets $49.6m cash injection as Archer Capital takes over
OIO greenlights NZP sale to Boston private equity fund
General Business,
84778
true
Subscribe Login